⌘K
t
Arecor Therapeutics plc announced that Chair Andrew Richards, CEO Sarah Howell, and CSO Jan Jezek purchased ordinary shares. On 19 May 2025, Mr. Richards acquired 31,750 shares at £0.4697 each and Ms. Howell acquired 21,077 shares at £0.4697 each. Mr. Jezek purchased 10,000 shares at £0.4700 each on 20 May 2025.
| Date | 21 May 2025 |
| Time | 07:00:10 |
| Category | Director/PDMR dealings |
| ID | 4864J |
Arecor Therapeutics plc
("Arecor", the "Company" or the "Group")
Director/PDMR Dealing
Cambridge, UK, 21 May 2025. Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, announces that Andrew Richards (Chair), Sarah Howell (Chief Executive Officer) and Jan Jezek (Chief Scientific Officer) have all purchased ordinary shares of £0.01 each in the capital of the Company ("Ordinary Shares"). Details are included in the table below.
|
Name |
Number of Ordinary Shares purchased |
Price (£) |
Total beneficial interest (Ordinary Shares) |
Total beneficial interest (%) |
|
Andrew Richards |
31,750 |
0.4697 |
318,361 |
0.84% |
|
Sarah Howell |
21,077 |
0.4697 |
905,481 |
2.40% |
|
Jan Jezek |
10,000 |
0.4700 |
417,808 |
1.11% |
-ENDS-
For more information, please contact:
|
Arecor Therapeutics plc |
www.arecor.com |
|
Dr Sarah Howell, Chief Executive Officer |
Tel: +44 (0) 1223 426060 Email: info@arecor.com |
|
David Ellam, Chief Financial Officer |
Tel: +44 (0) 1223 426060 Email: info@arecor.com |
|
|
|
|
Singer Capital Markets Advisory LLP (NOMAD and Broker) |
|
|
Phil Davies, Sam Butcher |
Tel: +44 (0) 20 7496 3000 |
|
|
|
|
ICR Healthcare |
|
|
Chris Gardner, David Daley, Lindsey Neville |
Tel: +44 (0) 20 3709 5700 Email: arecor@icrhealthcare.com |
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. For further details please see our website, www.arecor.com
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|
|
a) |
Name |
Andrew Richards |
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Chair |
|
b) |
Initial notification/Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Arecor Therapeutics plc |
|
b) |
LEI |
98450093D1213A8DDD58 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument |
Ordinary Shares |
|
b) |
Identification Code |
GB00BMWLM973 |
|
c) |
Nature of the transaction |
Purchase of Ordinary Shares |
|
d) |
Price(s) and volume(s) |
£0.4697 and 31,750 Ordinary Shares |
|
e) |
Aggregated information - Aggregated volume - Aggregated price |
N/A |
|
f) |
Date of the transaction |
19 May 2025 |
|
g) |
Place of the transaction |
London Stock Exchange, AIM |
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|
|
a) |
Name |
Sarah Howell |
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Chief Executive Officer |
|
b) |
Initial notification/Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Arecor Therapeutics plc |
|
b) |
LEI |
98450093D1213A8DDD58 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument |
Ordinary Shares |
|
b) |
Identification Code |
GB00BMWLM973 |
|
c) |
Nature of the transaction |
Purchase of Ordinary Shares |
|
d) |
Price(s) and volume(s) |
£0.4697 and 21,077 Ordinary Shares |
|
e) |
Aggregated information - Aggregated volume - Aggregated price |
N/A |
|
f) |
Date of the transaction |
19 May 2025 |
|
g) |
Place of the transaction |
London Stock Exchange, AIM |
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|
|
a) |
Name |
Jan Jezek |
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Chief Scientific Officer |
|
b) |
Initial notification/Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Arecor Therapeutics plc |
|
b) |
LEI |
98450093D1213A8DDD58 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument |
Ordinary Shares |
|
b) |
Identification Code |
GB00BMWLM973 |
|
c) |
Nature of the transaction |
Purchase of Ordinary Shares |
|
d) |
Price(s) and volume(s) |
£0.4700 and 10,000 Ordinary Shares |
|
e) |
Aggregated information - Aggregated volume - Aggregated price |
N/A |
|
f) |
Date of the transaction |
20 May 2025 |
|
g) |
Place of the transaction |
London Stock Exchange, AIM |